-
Immunity: "harmful" fat may inhibit the body's ability to attack cancer cells by killer T cells
Time of Update: 2021-06-22
Recently, in a research report titled "Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors" published in the international journal Immunity , scientists from Salk Institute and other institutions Studies have found that the tumor microenvironment contains a large number of oxidized lipid molecules.
-
How does rheumatism happen?
Time of Update: 2021-06-22
Viviana Marzaioli from University College Dublin, National University of Ireland, brought the title "CD209+/CD14+Dendritic Cells are enriched and activated at the site of inflammation and are modulated "by JAK/STAT signalling" report, introduced the pathogenic role of CD209+/CD14+ DC cells in inflammatory arthritis (IA) .
-
Science Advances Significant progress!
Time of Update: 2021-06-22
On June 11, 2021, the Zhang Hongkai team of Nankai University published a research paper titled "High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics" in Science Advances.
-
Nat Commun: New molecular classification promotes precision treatment strategies for primary Sjogren’s syndrome
Time of Update: 2021-06-21
In this study, the researchers reported the relevant molecular typing scheme of Sjogren’s syndrome patients in a descriptive cohort based on multi-omics analysis of whole blood samples from a cohort of more than 300 European patients, and similar numbers Sample data of healthy volunteers matched by age and gender .
-
Immunity: COVID-19 human brain tissue analysis reveals the interaction between neuroinflammation and microglia-T cells
Time of Update: 2021-06-21
This article analyzes the cellular composition and immune phenotype of the central nervous tissue of patients who died of COVID-19 and found that a deep immune activation controlled by CD8 + T cell clusters affects blood vessels and cell-microglia crosstalk.
-
Blood: Long-term prognosis after gene therapy for patients with adenosine deaminase severe combined immunodeficiency (ADA SCID)
Time of Update: 2021-06-21
Patients who lack functional adenosine deaminase activity will develop severe combined immunodeficiency (ADA SCID) and can be treated with ADA enzyme replacement therapy (ERT), allogeneic hematopoietic stem cell transplantation (HSCT) or autologous HSCT with genetically corrected cells ( Gene Therapy-GT) Treatment of ImmunityA cohort of 10 ADA SCID patients aged 3 months to 15 years old received GT treatment in a phase II clinical trial from 2009 to 2012 .
-
Nat Commun: JAK inhibitor tofacitinib in the treatment of systemic lupus erythematosus
Time of Update: 2021-06-21
Immune blood vesselPrevious studies have shown that the risk of cardiovascular disease (CVD) and premature atherosclerosis is significantly increased in SLE, especially in young women .
In this study, researchers conducted a randomized, double-blind, placebo-controlled clinical trial of tofacitinib in SLE subjects (ClinicalTrials.
-
The official title evaluation gives preference to such doctors
Time of Update: 2021-06-20
A batch of hospitals will be selected to carry out a pilot model of integrated traditional Chinese and western medicine, and explore the establishment of a multidisciplinary diagnosis and treatment system of traditional Chinese and western medicine in departments such as rheumatism, immunity, tumor, blood, vascular disease, and gastrointestinal hepatobiliary surgery .
-
The U.S. FDA approves the expansion of Ultomiris...
Time of Update: 2021-06-20
S. Food and Drug Administration (FDA) has approved the expansion of the use of Ultomiris (ravulizumab-cwvz) to include paroxysmal nocturnal hemoglobinuria (PNH) children (one month and older) and Adolescent patients .
-
Bristol-Myers Squibb
Time of Update: 2021-06-20
In December 2020, the marketing application (JXSS2000056/JXSS2000054) of the combination therapy intended for the treatment of unresectable non-epithelial malignant pleural mesothelioma in adult patients was approved by the Center for Drug Evaluation (CDE) for priority review .
-
The highest total remission rate is nearly 90%!
Time of Update: 2021-06-19
This trial, called ARROW, shows that pratinib is a new, well-tolerated, and effective once-daily oral treatment option for RET-fusion-positive NSCLC patients and RET-mutant thyroid cancer patients .
-
The first Alport syndrome (hereditary nephritis) drug!
Time of Update: 2021-06-19
Recently, the company announced that the US Food and Drug Administration (FDA) has accepted a new drug application (NDA) for bardoxolone methyl (bardoxolone) for the treatment of chronic kidney disease (CKD) caused by Alport syndrome .
-
Innovative medicine for neuromyelitis optica spectrum disorder (NMOSD)!
Time of Update: 2021-06-19
News on April 24, 2021 // --Roche recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting the approval of Enspryng (satralizumab) as a monotherapy or combined immunosuppressive therapy ( IST), used to treat neuromyelitis optica spectrum disorder (NMOSD) adolescents (age ≥ 12 years) and adult patients with positive anti-aquaporin-4 antibody (AQP4-IgG) .
-
Ann Oncol: olaparib monotherapy may be expected to treat early-stage triple-negative breast cancer
Time of Update: 2021-06-19
Annals of Oncology Olaparib monotherapy may be expected as the main treatment for non-selective triple-negative breast cancer patients; and targeted therapy for early-stage breast cancer may provide help to significantly increase the success rate of treatment .
-
New medicine for psoriasis!
Time of Update: 2021-06-19
Meeting the treatment of mild to moderate plaque psoriasis compared to placebo, Otezla significantly improved the severity of the disease, body surface area (BSA) regardless of how patients affected by the disease .
-
Domestic PD-1 therapy! Fuhong Henlius's Slulimumab (serplulimab, HLX10) was accepted by the National Food and Drug Administration for the treatment of MSI-H/dMMR solid tumors!
Time of Update: 2021-06-19
News on April 23, 2021 // --Henlius recently announced that its independently developed and innovative PD-1 inhibitor slulimumab (serplulimab, HLX10, recombinant humanized anti-PD-1 monoclonal antibody) injection has been treated with standard treatment The failed, unresectable or metastatic highly microsatellite unstable (MSI-H) solid tumor indication marketing registration application (NDA) was officially accepted by the National Medical Products Administration (NMPA), and it is planned to be included in the priority review process .
-
Nature: Organ tissues may become more and more immune throughout the life stage
Time of Update: 2021-06-19
Recently, in a research report entitled "Expansible residence decentralizes immune homeostasis" published in the international journal Nature , scientists from the University of Minnesota School of Medicine and other institutions have discovered through research that the body’s organs may become More and more immune, and this view may change the views of scientists on the rules of immunization and the function of the body's immune system .
-
Tianjing Bio-IL-6 trans-signaling pathway inhibitor olamkicept has been successful in the treatment of ulcerative colitis (UC) phase 2 clinical trial!
Time of Update: 2021-06-19
The study has reached the primary endpoint and key secondary endpoints: (1) After 12 weeks of treatment, with placebo Compared with the drug group, the 600mg dose olamkicept group showed a significantly higher clinical response rate (p=0.
-
Nat Commun: Significant progress!
Time of Update: 2021-06-19
Related research results were recently published in the journal Nature Communications, with the title of the paper "Human anogenital monocyte-derived dendritic cells and langerin+cDC2 are major HIV target cells" .
-
New medicine for atopic dermatitis (AD)!
Time of Update: 2021-06-19
Eli Lilly Olumiant is the world's first JAK inhibitor approved for the treatment of atopic dermatitis (AD) by the FDA In an analysis of the BREESE-AD5 Phase 3 trial, as measured by the percentage of change from baseline, Olumiant improved the severity and scope of AD as early as one week after treatment, as well as other major changes compared to placebo.
